Gustafson C E, Young J, Leggett B, Searle J, Chenevix-Trench G
Queensland Institute of Medical Research, Brisbane, Australia.
Br J Cancer. 1994 Sep;70(3):395-7. doi: 10.1038/bjc.1994.315.
We have examined a series of human colorectal adenomas, carcinomas and cell lines derived from human colorectal cancer for loss of heterozygosity (LOH) on chromosome 11q22-23 by polymerase chain reaction (PCR) amplification of a microsatellite polymorphism of the dopamine D2 receptor (DRD2) locus. LOH was demonstrated in 5/30 (16.7%) adenomas and 23/68 (33.8%) carcinomas. Only 2/20 (10%) cell lines showed homozygosity which could potentially be as a consequence of LOH. This moderate level of loss in the tumour samples was probably not an underestimation as a result of excessive stromal contamination because high rates (68-77%) have been detected in the same samples on chromosomes 17 and 18. In contrast to a previous report, LOH in carcinomas at 11q22-23 occurred at a lower frequency and was not associated with Dukes' stage, degree of differentiation, mucin production or the location of the cancer. However, a significant association was found between LOH on chromosome 11 and chromosome 14. Thus, inactivation of any putative tumour-suppressor gene at 11q22-23 by LOH is not a very common event in the development of colorectal tumours, but may be biologically significant if accompanied by chromosome 14 deletions.
我们通过对多巴胺D2受体(DRD2)基因座微卫星多态性进行聚合酶链反应(PCR)扩增,检测了一系列人类结肠直肠腺瘤、癌以及源自人类结肠直肠癌的细胞系,以研究11q22 - 23染色体上的杂合性缺失(LOH)情况。在30个腺瘤中有5个(16.7%)出现LOH,68个癌中有23个(33.8%)出现LOH。仅20个细胞系中有2个(10%)显示纯合性,这可能是LOH的结果。肿瘤样本中这种中等程度的缺失可能并非因基质污染过多而被低估,因为在相同样本的17号和18号染色体上已检测到高频率(68 - 77%)的缺失。与之前的一份报告相反,11q22 - 23处癌中的LOH发生频率较低,且与杜氏分期、分化程度、黏液产生或癌症位置无关。然而,在11号染色体和14号染色体的LOH之间发现了显著关联。因此,通过LOH使11q22 - 23处任何假定的肿瘤抑制基因失活在结肠直肠肿瘤发生过程中并非常见事件,但如果伴有14号染色体缺失可能具有生物学意义。